Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Posch

Showing results (161-170 of 166) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 166 results.
Statistics in Medicine|February 23, 2022
Statistical advising: Professional development opportunities for the biostatisticianMarissa LeBlanc, Corina S Rueegg, Nural Bekiroğlu, et al.
Carcinogenesis|November 23, 2012
Genome-wide CpG island methylation analyses in non-small cell lung cancer patientsGerwin Heller, Valerie N Babinsky, Barbara Ziegler, et al.
Vaccine|November 2, 2023
Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)Julia M Neuhann, Jannik Stemler, Antonio J Carcas, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 11, 2024
Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)Jannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 8, 2026
Immunogenicity, reactogenicity and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) - final reportJannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, et al.
The Lancet. Respiratory Medicine|August 8, 2021
Variations in end-of-life practices in intensive care units worldwide (Ethicus-2): a prospective observational studyAlexander Avidan, Charles L Sprung, Joerg C Schefold, et al.
Pageof 17

Showing results (161-170 of 166) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 166 results.
Statistics in Medicine|February 23, 2022
Statistical advising: Professional development opportunities for the biostatisticianMarissa LeBlanc, Corina S Rueegg, Nural Bekiroğlu, et al.
Carcinogenesis|November 23, 2012
Genome-wide CpG island methylation analyses in non-small cell lung cancer patientsGerwin Heller, Valerie N Babinsky, Barbara Ziegler, et al.
Vaccine|November 2, 2023
Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)Julia M Neuhann, Jannik Stemler, Antonio J Carcas, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 11, 2024
Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)Jannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 8, 2026
Immunogenicity, reactogenicity and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) - final reportJannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, et al.
The Lancet. Respiratory Medicine|August 8, 2021
Variations in end-of-life practices in intensive care units worldwide (Ethicus-2): a prospective observational studyAlexander Avidan, Charles L Sprung, Joerg C Schefold, et al.
Pageof 17